drugset / Trial / NCT00320294

ILF With/Without Cisplatin for Advanced Gastric Cancer

NCT00320294 ↗

Phase 2 Unknown 86 enrolled Gachon University Gil Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.

Timeline

Start
2005-02
Primary completion
—
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 30 mg/m2 —
Background Irinotecan Small molecule 150 mg/m2 —

Indications